title: Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation.
abstract: The management of Hodgkin's lymphoma (HL) recurring after allogeneic stem cell transplantation is challenging. We retrospectively describe 18 adults treated with bendamustine followed by escalated donor lymphocyte infusion. Hematological toxicity was manageable (39% grade III to IV neutropenia and 28% grade III to IV thrombocytopenia). The overall response rate was 55%, with 3 complete and 7 partial responses. Median overall and progression-free survival were 11 (range, 1 to 52) and 6 (range, 1 to 28) months, respectively. One-year overall survival of responders (complete or partial) was 70% (95% confidence interval, 42% to 98%), although it was only 16% for nonresponders (n = 8). Our data show that bendamustine followed by donor lymphocyte infusion is feasible and can be efficacious as salvage treatment in HL relapsing after an allograft.
authors.affiliation: Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy.
authors.forename: Elisa
authors.initials: E
authors.lastname: Sala
authors.affiliation: Humanitas Cancer Centre, Istituto Clinico Humanitas, via Manzoni 56, 20089 Rozzano, Milano, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Crocchiolo
authors.affiliation: Humanitas Cancer Centre, Istituto Clinico Humanitas, via Manzoni 56, 20089 Rozzano, Milano, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Gandolfi
authors.affiliation: Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Bruno-Ventre
authors.affiliation: Humanitas Cancer Centre, Istituto Clinico Humanitas, via Manzoni 56, 20089 Rozzano, Milano, Italy.
authors.forename: Stefania
authors.initials: S
authors.lastname: Bramanti
authors.affiliation: Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy.
authors.forename: Jacopo
authors.initials: J
authors.lastname: Peccatori
authors.affiliation: Humanitas Cancer Centre, Istituto Clinico Humanitas, via Manzoni 56, 20089 Rozzano, Milano, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Sarina
authors.affiliation: Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy.
authors.forename: Consuelo
authors.initials: C
authors.lastname: Corti
authors.affiliation: Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy.
authors.forename: Fabio
authors.initials: F
authors.lastname: Ciceri
authors.affiliation: Humanitas Cancer Centre, Istituto Clinico Humanitas, via Manzoni 56, 20089 Rozzano, Milano, Italy.
authors.forename: Armando
authors.initials: A
authors.lastname: Santoro
authors.affiliation: Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy. Electronic address: marktel.sarah@hsr.it.
authors.forename: Sarah
authors.initials: S
authors.lastname: Marktel
authors.affiliation: Humanitas Cancer Centre, Istituto Clinico Humanitas, via Manzoni 56, 20089 Rozzano, Milano, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Castagna
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008214:Lymphocytes; D009364:Neoplasm Recurrence, Local; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000379:methods*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride
keywords: Allogeneic stem cell transplantation; Bendamustine; Donor lymphocyte infusion; Hodgkin's lymphoma